Optimization of pyrrolidinone based HIV protease inhibitors

  • Bioorg Med Chem Lett. 2005 Jan 3;15(1):81-4. doi: 10.1016/j.bmcl.2004.10.029.
Ronald G Sherrill  1 ,  C Webster Andrews ,  William J Bock ,  Ronda G Davis-Ward ,  Eric S Furfine ,  Richard J Hazen ,  Randy D Rutkowske ,  Andrew Spaltenstein ,  Lois L Wright
Affiliations
  • 1. GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA. [email protected]
PMID: 15582415 DOI: 10.1016/j.bmcl.2004.10.029
Abstract

Optimization of P1-substituted pyrrolidinone based HIV Protease Inhibitors has yielded analogs with very potent Antiviral activity.